|
Neoantigen Peptide Vaccine Clinical Trials
3 actively recruiting trials across 2 locations
Pipeline
Phase 1: 1Phase 1/2: 1
Top Sponsors
- The First Affiliated Hospital of Nanchang University1
- Mayo Clinic1
- Fred Hutchinson Cancer Center1
Indications
- Cancer3
- Pathologic Stage IIID Cutaneous Melanoma AJCC v82
- Pathologic Stage IIIC Cutaneous Melanoma AJCC v82
- Unresectable Lung Non-Small Cell Carcinoma2
- Anatomic Stage IV Breast Cancer AJCC v82
Other1 trial
Jacksonville, Florida1 trial
Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors
Mayo Clinic in Florida
Phase 1/2
Seattle, Washington1 trial
Personalized Neo-Antigen Peptide Vaccine for the Treatment of Stage IIIC-IV Melanoma, Hormone Receptor Positive HER2 Negative Metastatic Refractory Breast Cancer or Stage III-IV Non-Small Cell Lung Cancer
Fred Hutch/University of Washington Cancer Consortium
Phase 1
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.